Clinical Trial Update: An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

View source ↗

Summary

This entry reports the completion of an observational safety study of vemurafenib (Zelboraf) in patients with BRAF V600 mutation-positive unresectable or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Zelboraf (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Status: COMPLETED